Novo Nordisk A/S (NYSE:NVO) Shares Sold by Bay Colony Advisory Group Inc d b a Bay Colony Advisors

Bay Colony Advisory Group Inc d b a Bay Colony Advisors reduced its position in Novo Nordisk A/S (NYSE:NVO) by 21.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,754 shares of the company’s stock after selling 2,923 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Novo Nordisk A/S were worth $925,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of NVO. Marco Investment Management LLC increased its stake in shares of Novo Nordisk A/S by 1.5% in the third quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock worth $798,000 after buying an additional 100 shares during the last quarter. Carr Financial Group Corp increased its position in shares of Novo Nordisk A/S by 5.1% in the 3rd quarter. Carr Financial Group Corp now owns 2,100 shares of the company’s stock worth $250,000 after purchasing an additional 101 shares during the last quarter. Menard Financial Group LLC raised its stake in shares of Novo Nordisk A/S by 0.8% in the 3rd quarter. Menard Financial Group LLC now owns 12,283 shares of the company’s stock valued at $1,463,000 after purchasing an additional 102 shares in the last quarter. Optimist Retirement Group LLC lifted its position in shares of Novo Nordisk A/S by 4.3% during the third quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company’s stock worth $327,000 after purchasing an additional 112 shares during the last quarter. Finally, Financial Counselors Inc. grew its stake in Novo Nordisk A/S by 1.1% in the third quarter. Financial Counselors Inc. now owns 11,009 shares of the company’s stock worth $1,311,000 after purchasing an additional 115 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NVO has been the topic of several research reports. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Trading Down 1.0 %

NYSE NVO opened at $87.19 on Friday. The firm’s 50 day moving average price is $84.91 and its two-hundred day moving average price is $105.29. The stock has a market cap of $391.25 billion, a price-to-earnings ratio of 26.50, a PEG ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a twelve month low of $77.82 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a $0.7874 dividend. The ex-dividend date is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.